IL6 and neoplasm: Bilirubin level and serum tumor markers such as carbohydrate antigen 19-9(CA19-9), interleukin-6 (IL-6) and neutrophil gelatinase-associated lipocalin do not have the power to reliably differentiate malignant from benign stricture [5].